REMEGEN(688331)2025-01-16 07:46Revenue Projections - The company expects a revenue of approximately CNY 1,715 million for 2024, an increase of about CNY 632 million or 58% compared to the previous year[3]. - In 2023, the company reported a revenue of CNY 1,083 million and a total loss of CNY 1,511 million[6]. Net Loss Forecast - The projected net loss attributable to the parent company for 2024 is approximately CNY 1,470 million, a decrease of about CNY 41 million or 3% compared to the previous year[3]. - The expected net loss attributable to the parent company, excluding non-recurring gains and losses, is approximately CNY 1,498 million, a decrease of about CNY 45 million or 3% compared to the previous year[3]. Research and Development - The company is advancing its new drug research pipeline, with multiple innovative drugs in critical trial stages, leading to increased R&D investment[8]. Sales Performance - Sales revenue from Taitasip and Vidisitamab is growing rapidly, contributing to an increase in product gross margin[8]. - The sales expense ratio has significantly decreased, indicating improved operational efficiency[8]. Financial Reporting and Uncertainties - The total amount of non-recurring gains and losses for the year has not changed significantly[9]. - As of the announcement date, the company has not identified any major uncertainties affecting the accuracy of the performance forecast[10]. - The forecast data is preliminary and subject to change pending the audited financial report for 2024[11].